VOGX
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
| 期間 | EPS | 売上 | FCF |
|---|---|---|---|
| 2026 Q3 | -0.47 | $0 | -$3M |
| 2026 Q2 | -0.03 | $0 | $27,140 |
| 2026 Q1 | -0.03 | $0 | — |
| 2025 Q4 | 0.00 | $0 | — |